Pall's prion-removal technology presented to FDA

New York, Oct. 31 - Pall Corp. said it presented the latest research results on its prion technology to remove transmissible spongiform encephalopathies from blood to the Food and Drug Administration.

Pall's Leukotrap Affinity Prion Reduction Filter is a Council of Europe marked technology that removes prions from red blood cells, the most common component used in blood transfusions.

Transmissible spongiform encephalopathies include vCJD, the human form of bovine spongiform encephalopathy or mad cow disease.

The research shown to the FDA provides "a feasible means for quality control for blood banks in their prion reduction process since the plasma protein can easily be measured with currently available analytical methods," said Samuel Coker, principal scientist and technical director of Pall Medical, in a news release.

Studies showed about 99.9% prion removal across all conditions.

Pall is an East Hills, N.Y. company working on filtration, separations and purification.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.